Immune Monitoring of Hepatitis C Under DAA Therapy (IMHC)

University of Regensburg (UR)

Status: Unknown

Conditions: Hepatitis C

Study type: Observational

Funder types: Other

Identifiers

NCT02904603

IM-HC-1516

Details and patient eligibility

About

Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• written consent, age, HCV-RNA positive, DAA therapy

Exclusion criteria